Share It

Top Menu

Friday, April 20, 2012

As the bridge between genotype and phenotype, the field of epigenetic research has enormous potential to progress diagnosis and therapy in oncology and the wider disease spectrum.The enormous pan-disease potential of epigenetic based drugs is now beginning to encourage floods of investment as excellent basic research is being translated into clinical utility. In 2009, sales of the 4 approved epigenetic drugs reached $519m. Now, such is the pace of development that Global Industry Analysts are expecting market value to grow to $18.2bn by 2015.Are you prepared for the leap forward in epigenetic therapeutics?Realizing such immense potential will require thought leaders to address very specific challenges. Calls to action are being made to identify and validate new targets and confront attendant issues in assay development and the availability of quality reagents. Industry and academia also agree that more must be done to productively integrate recent advances in the basic and clinical sciences.

With strong representation and candid discussion guaranteed from senior level figures at Pfizer, GSK, Celgene, Constellation Pharmaceuticals and Epizyme, the 3rd World Epigenetics Summit will address these concerns directly and deliver commercially directed insight into the most pressing technical and strategic issues at hand.

This year’s World Epigenetics Summit will look to build on the successes of our two previous events and thereby provide a platform to help speed the development of better, more effective epigenetic drugs.Why attend?• Get an up-to-the-minute snapshot of the very latest epigenetic target classes for disease therapy from Epizyme, GSK and Pfizer• Discover the excitement that epigenetic drugs are generating in the clinic withStephen Baylin• Explore the potential of epigenetic modulation in non-oncological disease indications with Sasha Tarakhovsky and Cambridge University Hospitals• Uncover the impact that epigenomics will make on personalized medicine with4SC• Find out how to optimize methods, assays and practices throughout the production pipeline so you can maximize the value of your R&D spendWho should attend:• Epigenetic drug developers looking to progress epigenetic drugs into the clinic and meet business leaders• Pharma companies with a strong interest in epigenetic drug development• Technology specialists seeking to highlight novel platforms, assays and equipment• Business development professionals assessing pipeline investment opportunities• Scientists and academics working in medicinal chemistry and the wider epigenetic spectrum